- Home
- AXTA vs MDGL Comparison
AXTA vs MDGL Comparison
Compare AXTA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXTA | MDGL |
|---|---|---|
| Founded | 1910 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 12.5B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | AXTA | MDGL |
|---|---|---|
| Price | $33.42 | $500.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $36.36 | ★ $580.77 |
| AVG Volume (30 Days) | ★ 3.5M | 347.1K |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.67 | N/A |
| EPS | ★ 2.09 | N/A |
| Revenue | ★ $5,166,000,000.00 | $740,640,000.00 |
| Revenue This Year | N/A | $435.62 |
| Revenue Next Year | $2.01 | $52.67 |
| P/E Ratio | $16.05 | ★ N/A |
| Revenue Growth | N/A | ★ 864.21 |
| 52 Week Low | $26.28 | $265.00 |
| 52 Week High | $38.37 | $615.00 |
Technical Indicators
Market Signals| Indicator | AXTA | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.84 | 35.65 |
| Support Level | $31.61 | $487.19 |
| Resistance Level | $33.61 | $589.98 |
| Average True Range (ATR) | 0.57 | 21.98 |
| MACD | -0.04 | -10.54 |
| Stochastic Oscillator | 88.86 | 13.99 |
Price Performance
Historical ComparisonAbout AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.